Sirona Announces Resignation of Neil Belenkie

VANCOUVER, BC--(Marketwired - June 23, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) (the "Company") announces that Neil Belenkie has resigned as Chief Executive Officer of the Company. Neil has agreed to stay on with the company to assist in the transition until July 18, 2014. The Company thanks Mr. Belenkie for his hard work over the past 2 years and wishes him well in his future endeavors.

Dr. Howard Verrico has been appointed interim CEO by the Board of Directors.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.